Zydus Lifesciences shares rise 3% on USFDA approval for Dasatinib tablets

Zydus Lifesciences

Zydus Lifesciences share price gained more than 3 percent in the early trade on March 6 after the company received final approval from USFDA for Dasatinib Tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg.

At 09:25am, Zydus Lifesciences was quoting at Rs 916.10, up Rs 28.55, or 3.22 percent, on the BSE.

The tablets will be manufactured at the company’s facility in Ahmedabad and use for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) in chronic phase.

It is also used to treat adults with chronic, accelerated or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib and adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) with resistance or intolerance to prior therapy.

The tablets will be produced at Zydus Lifesciences Ltd (SEZ), Ahmedabad.

Catch all the market action on our live blog

Also, the company launched ANVIMO (Letermovir), a breakthrough in the prevention of Cytomegalovirus (CMV) infection for haematopoietic stem cell transplant (HSCT) and kidney transplant patients. ANVIMO will be available in dosages of 240 mg and 480 mg.

On March 4, the company announced its focus on the development of a combination vaccine against shigellosis and typhoid.

The company will carry out early-stage development, animal immunogenicity studies and regulatory preclinical toxicology studies for this combination vaccine.

Zydus Lifesciences had reported a 30 percent increase in its consolidated net profit at Rs 1,023 crore for the quarter ended December 31, 2024.